Can a nasal spray slow Alzheimer's? new trial aims to find out
NCT ID NCT07178678
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial will test whether a nasal spray called NeuroEPO can help maintain thinking and memory in people with mild to moderate Alzheimer's disease. About 90 adults aged 50 and older will receive either NeuroEPO or a placebo three times a week for one year. Researchers will measure changes in cognitive function and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- NeuroEPO (a form of erythropoietin given as a nasal spray)
- What this could lead to
- If it works, this could point toward a new way to slow memory loss and thinking problems in people with early-to-moderate Alzheimer's disease.
- What could go wrong
- This is a small, early-phase trial (90 people) testing a drug that has not been proven effective for Alzheimer's. It may show no benefit or cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients \>= 50 years of age, to reflect the population that will be treated and to avoid younger populations who may be suffering dementia from a cause other than Alzheimer's Disease. * Patients with Global Deterioration Scale (GDS) between 3 to 5 points (inclusive). * Clinical Dementia Rating (CDR) - GS score 1-2 at screening. * Patients with permeable airways. * Patients (or caregiver, if the patient cannot) grant consent to participate in the study by signing the informed consent form. * Patient with caregiver is physically and mentally willing to collaborate with the investigation. * Mini-Mental State Examination (MMSE) score between 14 and 26 (inclusive) at screening Exclusion Criteria: * Evident mental disability or other limitation that prevents the patient or caregiver from administering the study evaluations. * Patients with neurological symptoms or signs that suggest another cause of dementia. * Skull trauma or recent intracranial surgery. * Known clotting disorders. * Use of anticoagulants, a medication to prevent harmful blood clots (warfarin, heparin or NOAC). * Patients where coexistence of another disease or condition that may lead to significant disability (cancer, septic embolism, endocarditis, myeloproliferative disease, creatinine\> 3 mg / dl (265µmol / L), hyperkalemia \> 5.0 mmol / L, chronic/severe liver or kidney or heart disorders. * Patients with a history of hypersensitivity to rhEPO. * Patients with known allergy to any ingredients of the product. * Patients who present nasal irritation (sneezing) or a runny nose before starting treatment. * Patients who present asthma attack at the beginning of the treatment. * Patients receiving treatment with AChE-I or Memantine who are not stable for 12-weeks prior to screening. * Patients receiving treatment with psychoactive that can compromise the clinical trial results or neuropsychological tests. * Patients with a history of alcoholism and/or drug dependence. * Patients with chronic rhinosinusitis. * Have a history of abnormal nasal or sinus symptoms. * Have prior skull fracture or abnormality (nasal defect, deviated septum). * Have recent nasal trauma (fracture in the last 2 months). * Have any prior sinus or nose surgery (rhinoplasty). * Have known bleeding problem (low platelets-thrombocytopenia), recurrent nose bleeds (\>3 year). * Have acute inflammation inside the nose. * Congenital cranial facial disorders.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mild Alzheimer'S disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Saskatchewan
Saskatoon, Saskatchewan, S7N5E5, Canada